Physician profile
Rupal Kothari
NPI 1124094073
$60,549.03
in general payments reported to CMS, 2019-2025
39 companies · $11K in 2025
The $11K reported for 2025 was more than what 93% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,531 · 2020: $2,986 · 2021: $3,384 · 2022: $9,469 · 2023: $8,867 · 2024: $19K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Food and Beverage: $7,941 · Travel and Lodging: $2,003 · Education: $35.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $29,200.00 |
| Food and Beverage | $7,940.94 |
| Travel and Lodging | $2,002.90 |
| Education | $35.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $50,741.29 | 2019-2025 | |
| Janssen Biotech, INC. | $1,338.83 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $1,241.24 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Celgene Corporation | $1,057.83 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $979.77 | 2019-2025 | Xifaxan, Trulance |
| Pfizer INC. | $792.16 | 2019-2025 | |
| Qol Medical, LLC | $524.75 | 2022-2025 | Sucraid, Sucraid |
| Lilly USA, LLC | $425.10 | 2023-2025 | Omvoh |
| Daiichi Sankyo INC. | $309.64 | 2019-2025 | Injectafer |
| Merck Sharp & Dohme LLC | $290.02 | 2019-2023 | Dificid |
| Intercept Pharmaceuticals, INC. | $287.69 | 2019-2024 | Ocaliva |
| Genzyme Corporation | $237.39 | 2022-2025 | |
| Ardelyx, INC. | $236.41 | 2022-2025 | Ibsrela |
| Gilead Sciences, INC. | $222.59 | 2020-2025 | Epclusa |
| Ferring Pharmaceuticals INC. | $215.58 | 2019-2024 | Rebyota |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $211.36 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $198.85 | 2022-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $152.87 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $121.46 | 2024-2025 | Resmetirom, Rezdiffra |
| Nestle Healthcare Nutrition INC. | $113.48 | 2021-2023 | |
| Amgen INC. | $96.92 | 2020-2025 | Amjevita, Avsola, Uplizna |
| Redhill Biopharma INC. | $95.85 | 2020-2022 | |
| Celltrion USA INC. | $92.25 | 2024 | Vegzelma, Zymfentra |
| Ironwood Pharmaceuticals, INC | $91.73 | 2020-2023 | Linzess |
| Evoke Pharma, INC. | $83.11 | 2023-2025 | Gimoti |
| Ipsen Biopharmaceuticals, INC | $60.17 | 2024-2025 | Iqirvo, Bylvay |
| Aimmune Therapeutics, INC. | $53.76 | 2023-2025 | Zenpep |
| Braintree Laboratories, INC. | $44.51 | 2019-2023 | Sutab |
| Endo Pharmaceuticals INC. | $32.65 | 2019 | |
| Axonics, INC. | $30.16 | 2022-2024 | Axonics |
| Shield Therapeutics INC | $26.47 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.83 | 2023 | Cyltezo |
| Capsovision, INC. | $20.08 | 2024 | Capsocam Plus |
| Inspire Medical Systems, INC. | $17.95 | 2025 | Inspire |
| Teleflex LLC | $17.83 | 2024 | Solesta |
| Novo Nordisk INC | $17.67 | 2025 | Wegovy |
| Alnylam Pharmaceuticals INC. | $17.51 | 2022 | |
| Medtronic, INC. | $13.53 | 2021 | |
| Fresenius Kabi USA, LLC | $12.74 | 2023 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rupal Kothari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.